Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JY108
- Development stage
- Unknown
- Lead developer
- Shenzhen Enduring Biotech
- Modality
- Antibody-Based Therapeutics
01
Overview
JY108: sourced facts only. name: "In this study, a bispecific antibody JY108 was developed to target CD19 and CD3e with much reduced affinities towards both targets (revealed by Biacore assay results)." [DOI:10.1158/1538-7445.am2024-3192]; target: "In this study, a bispecific antibody JY108 was developed to target CD19 and CD3e with much reduced affinities towards both targets (revealed by Biacore assay results)." [DOI:10.1158/1538-7445.am2024-3192]; target: "In this study, a bispecific antibody JY108 was developed to target CD19 and CD3e with much reduced affinities towards both targets (revealed by Biacore assay results)." [DOI:10.1158/1538-7445.am2024-3192]; developer: "1Shenzhen Enduring Biotech, Ltd., Shenzhen, China." [DOI:10.1158/1538-7445.am2024-3192]; modality: "In this study, a bispecific antibody JY108 was developed to target CD19 and CD3e with much reduced affinities towards both targets (revealed by Biacore assay results)." [DOI:10.1158/1538-7445.am2024-3192]; stage: "In addition, JY108 prolonged the survival of animals with Nalm6 brain metastasis more significantly than Blinatumomab at the same dosage." [DOI:10.1158/1538-7445.am2024-3192]
02
Targets
CD19 (B lymphocyte antigen CD19)CD3E (T-cell surface glycoprotein CD3 epsilon chain receptor)
Beyond the preview
Go deeper on JY108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JY108.